StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96+0.00 (0.00%)

Close on Nov 18, 2026Market cap $1.31BP/E –Yield –

Novavax net income

Net income is the profit left for shareholders after every expense, interest and tax.

Novavax's net income for the twelve months ending Jun 30, 2026 was -$247.73M, down 158.6% year over year. For fiscal 2025 it was $440.30M. The highest annual figure on record is $440.30M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$440.30M–
FY2024Dec 31, 2024-$187.50M–
FY2023Dec 31, 2023-$545.06M–
FY2022Dec 31, 2022-$657.94M–
FY2021Dec 31, 2021-$1.74B–
FY2020Dec 31, 2020-$418.26M–
FY2019Dec 31, 2019-$132.69M–
FY2018Dec 31, 2018-$184.75M–
FY2017Dec 31, 2017-$183.77M–
FY2016Dec 31, 2016-$279.97M–
FY2015Dec 31, 2015-$156.94M–
FY2014Dec 31, 2014-$82.95M–
FY2013Dec 31, 2013-$51.98M–
FY2012Dec 31, 2012-$28.51M–
FY2011Dec 31, 2011-$19.36M–
FY2010Dec 31, 2010-$35.71M–
FY2009Dec 31, 2009-$40.35M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$53.39M-150.1%
Q1 FY2026Mar 31, 2026-$9.49M-101.8%
Q4 FY2025Dec 31, 2025$17.53M–
Q3 FY2025Sep 30, 2025-$202.38M–
Q2 FY2025Jun 30, 2025$106.51M-34.4%
Q1 FY2025Mar 31, 2025$518.65M–
Q4 FY2024Dec 31, 2024-$81.03M–
Q3 FY2024Sep 30, 2024-$121.30M–
Q2 FY2024Jun 30, 2024$162.38M+179.9%
Q1 FY2024Mar 31, 2024-$147.55M–
Q4 FY2023Dec 31, 2023-$178.39M–
Q3 FY2023Sep 30, 2023-$130.78M–
Q2 FY2023Jun 30, 2023$58.01M–
Q1 FY2023Mar 31, 2023-$293.91M-244.5%
Q4 FY2022Dec 31, 2022-$182.25M–
Q3 FY2022Sep 30, 2022-$168.61M–
Q2 FY2022Jun 30, 2022-$510.49M–
Q1 FY2022Mar 31, 2022$203.41M–
Q4 FY2021Dec 31, 2021-$846.28M–
Q3 FY2021Sep 30, 2021-$322.43M–
Q2 FY2021Jun 30, 2021-$352.32M–
Q1 FY2021Mar 31, 2021-$222.72M–
Q4 FY2020Dec 31, 2020-$177.56M–
Q3 FY2020Sep 30, 2020-$197.31M–
Q2 FY2020Jun 30, 2020-$17.52M–
Q1 FY2020Mar 31, 2020-$25.86M–
Q4 FY2019Dec 31, 2019-$31.83M–
Q3 FY2019Sep 30, 2019-$18.04M–
Q2 FY2019Jun 30, 2019-$39.60M–
Q1 FY2019Mar 31, 2019-$43.22M–
Q4 FY2018Dec 31, 2018-$49.33M–
Q3 FY2018Sep 30, 2018-$44.57M–
Q2 FY2018Jun 30, 2018-$44.49M–
Q1 FY2018Mar 31, 2018-$46.35M–
Q4 FY2017Dec 31, 2017-$50.84M–
Q3 FY2017Sep 30, 2017-$44.61M–
Q2 FY2017Jun 30, 2017-$44.47M–
Q1 FY2017Mar 31, 2017-$43.85M–
Q4 FY2016Dec 31, 2016-$57.11M–
Q3 FY2016Sep 30, 2016-$66.25M–

More Novavax figures

See a number that looks wrong?